UK report on life sciences calls for greater freedoms for EU member states

15 January 2014
2019_biotech_test_vial_discovery_big

A new UK report condemns the European Union’s “anti-biotech legislation” which is damaging Europe’s bioscience economy.

George Freeman MP, the UK government advisor on life sciences between 2011 and 2013, has prepared the Fresh Start Project report on The EU impact on the UK Life Science sector. The report says: “The growing hostility of the EU to biotech, reflected in an increasing tide of ‘anti-biotech’ legislation, is having a damaging effect on the EU Bioscience economy, and risks condemning the EU – and by extension the UK – to the global slow lane in biotechnology.”

It adds: “Recent trends have led to growing concerns from academic researchers, companies and medical charities that the EU is in danger of becoming an increasingly unattractive territory for the new technologies and disciplines such as stem cell and regenerative tissue science, genomics and genetic epidemiology and the use of clinical data in large scale ‘BigData’ studies to help drive Stratified and Personalised Medicine.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology